All In Biotech

Drug Trial Radar · NCT06128967

A Multicenter, Adaptive, Randomized, doublE-blinded, Placebo-controlled Study in Participants With Long COVID-19: The REVIVE Trial

An Adaptive, Randomized, doublE-blind, Placebo-controlled, Prospective, Pharmacological interVention Study In Participants With Long COVID-19 Syndrome: REVIVE-TOGETHER Trial

Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 399 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

399

Actual

Start

Oct 18, 2023

Primary completion

Jul 1, 2025

Study completion Aug 1, 2025

Sponsor

Lead sponsor
CardresearchAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

IRB approval date 14-APR-2024 and public at https://plataformabrasil.saude.gov.br/login.jsf since IURB approval Long COVID is a multi-systemic condition comprising often severe and persistent symptoms (longer than 12 weeks) that follow a known episode of COVID-19 and cannot be explained by another medical condition. This condition is observed in up to 15% of all individuals after an acute episode of COVID-19, even in those who had a mild and oligosymptomatic SARS-CoV-2 infection. Around 40% of these patients present symptoms that significantly compromise their daily activities. There is increasing evidence that LONG COVID is accompanied by dysregulated, persistent and uncontrolled inflammation, often accompanied by the development of an autoreactive immune response, including autoantibodies. Symptoms can last months or years, particularly in cases of chronic fatigue syndrome, with significant proportions of individuals having significant chronic impairment, preventing the performance of work and social activities.

Conditions

  • Long COVID-19 Syndrome
  • Chronic Fatigue Syndrome

Interventions

  • Fluvoxamine Maleate 100 MGDrug

    Fluvoxamine Maleate 100 mg each pills

  • PlaceboDrug

    Placebo talc pills of same shape, color, weight if compared with active comparator

  • Metformin Extended Release Oral TabletDrug

    Metformin Extended release oral tablets of 750 mg each pill

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Improvement on Fatigue Severity Score Scale (FSS)Time frame: Day 60 after randomization

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • CARDRESEARCH - Cardiologia Assistencial e de Pesquisa

    Belo Horizonte, Minas Gerais, Brazil

  • City of Brumadinho

    Brumadinho, Minas Gerais, Brazil

  • Governador Valadares City Public Health Authority

    Governador Valadares, Minas Gerais, Brazil

  • City of Ibirité Public Health Authority

    Ibirité, Minas Gerais, Brazil

  • Sociedade Padrao de Educacao Superior

    Montes Claros, Minas Gerais, Brazil

  • Universidade Federal de Ouro Preto

    Ouro Preto, Minas Gerais, Brazil

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.